Pivotal Trial

Related by string. Pivotal Trials * pivotals . PIVOTAL . Pivotals . pivotal : pivotal Phase III . Pivotal CRM . pivotal undecided superdelegates . Pivotal filly . ACM Pivotal / trialed . trialing . trials . trial . Trials : Phase III clinical trials . Week Premium Trial . Phase III trials . placebo controlled clinical trials . randomized controlled trial * EMPOWER pivotal trial . Phase III Pivotal Trial *

Related by context. All words. (Click for frequent words.) 85 Phase III Clinical Trial 83 Phase III Trial 83 Pivotal Clinical Trial 82 Pivotal Study 82 Pivotal Phase III 81 Patient Enrollment 81 Phase IIb Trial 80 Phase 2b Clinical Trial 80 Clinical Trial Results 80 Meets Primary Endpoint 80 Completes Enrollment 80 Pivotal Phase 79 Completes Patient Enrollment 79 Phase IIb Clinical Trial 78 Phase 2b Study 78 Randomized Clinical Trial 78 Study Evaluating 78 Clinical Trial Evaluating 78 First Patient Enrolled 78 Combination REOLYSIN R 77 Phase 2a Clinical Trial 77 Receives Orphan Drug Designation 77 NDA Submission 77 Dose Ranging Study 77 Patients Treated With 77 Prospective Randomized 76 Phase 1b Clinical Trial 76 Initiate Phase 76 Phase III Trials 76 Phase III Clinical Trials 76 II Clinical Trial 76 Phase III Pivotal 76 Randomized Study 76 First Patient Treated 76 Patients Treated 76 FDA Approvals 76 Pivotal Trials 76 Long Term Efficacy 75 Phase 2b Trial 75 Investigational Compound 75 Improves Survival 75 Trial Evaluating 75 Clinical Study 75 Adjuvant Treatment 75 Files IND 75 Initiates Enrollment 75 Severe Sepsis 75 Drug Candidate 75 Initiates Phase II 75 JAK Inhibitor 75 Achieves Primary Endpoint 75 Expanded Indication 75 Drug Eluting Stent 75 Demonstrates Positive 75 Acute Ischemic Stroke 75 TM Drug Eluting 75 Initiates Clinical Trial 74 Initiate Clinical Trial 74 Monotherapy 74 Initiates Phase III 74 Oral Fingolimod 74 Confirmatory Phase 74 Controlled Study 74 Pooled Analysis 74 Prolongs Survival 74 Advanced Melanoma 74 Granted Orphan Drug 74 Lung Cancer Trial 74 Single Dose 74 IND Filing 74 FDA Accepts 74 Combination Treatment 74 PDUFA Date 74 Randomized Phase 73 Personalized Immunotherapy 73 Preclinical Data 73 Metastatic Colorectal Cancer 73 Endeavor Drug Eluting 73 Brentuximab Vedotin SGN 73 ENDEAVOR IV 73 Demonstrates Significant 73 Presents Positive 73 Well Tolerated 73 FOLOTYN ® 73 Investigational Treatment 73 Initiates Clinical 73 IND Application 73 Novel Oral 73 Acute Myocardial Infarction 73 Glatiramer Acetate 73 Hsp# Inhibitor 73 Hormone Refractory Prostate Cancer 73 Patients Enrolled 73 Eluting Coronary Stent System 73 Embolic Protection 73 Tezampanel 73 Cypher Sirolimus 73 Cutaneous T 73 Drug Eluting Stents 73 Liberte TM 73 Phase IIa Clinical Trial 73 Improves Outcomes 73 Clinical Study Shows 72 Unfractionated Heparin 72 Phase IIIb 72 Platelet Inhibition 72 Autologous Stem Cell Transplantation 72 Drug Eluting Stent System 72 Patient Outcomes 72 Eluting Stent 72 Randomized Evaluation 72 Rheumatoid Arthritis Patients 72 Phase 2a Trial 72 Ranolazine 72 Dose Escalation 72 Pharmacokinetic Study 72 Patient Enrolment 72 Efficacy Trial 72 Renal Cell Carcinoma 72 Randomized Double Blind 72 Previously Treated 72 Study Showed 72 IL# PE#QQR 72 Metastatic Melanoma 72 Successfully Completes Phase 72 First Patient Dosed 72 Coronary Stent 72 Neoadjuvant Chemotherapy 72 Submits NDA 72 Receives Orphan Drug 72 Intravitreal 72 Migraine Drug 72 Fondaparinux 72 Metastatic Prostate Cancer 72 Survival Benefit 72 Sapacitabine 71 Statistically Significant 71 Lupus Drug 71 Pafuramidine 71 Shows Promising 71 Clinical Evaluation 71 Microplasmin 71 Advanced Renal Cell 71 Initiates Clinical Trials 71 Lung Cancer Drug 71 Lupus Nephritis 71 Efficacy Results 71 Kidney Transplant Patients 71 TAXUS TM 71 Multicenter 71 Overactive Bladder 71 Relapsed Multiple Myeloma 71 Commences Phase 71 atypical Hemolytic Uremic Syndrome 71 PROMUS R 71 Oral Calcitonin 71 Present Preclinical Data 71 Initiate Phase III 71 Controlled Trial 71 TAXUS Element Paclitaxel Eluting 71 Drug Eluting Coronary Stent 71 Receives FDA Clearance 71 Files Investigational 71 Phase Ib Clinical Trial 71 Drug Fails 71 FDA Clearance 71 Phase III Pivotal Trial 71 Sirolimus Eluting Stent 71 R lenalidomide 71 Pulmonary Arterial Hypertension 71 Aflibercept 71 acute peripheral arterial 71 MIVI III 71 Phase IIIb clinical 71 Improved Survival 71 Adjuvant Therapy 71 Investigational Agent 71 Announces FDA Clearance 71 Antitumor Activity 71 Bone Graft 71 Fast Track Status 71 Restenosis 71 Clinical Outcome 71 Left Ventricular 71 catheter occlusion 71 Topline Results 71 Receives Positive Opinion 71 Heart Failure Patients 71 Elagolix 71 Treated Patients 71 Dupuytren Contracture 71 Romiplostim 71 Prostate Cancer Patients 71 Patients Undergoing 71 Feasibility Trial 70 Cholesterol Lowering Drug 70 Stent Restenosis 70 Cardiac Resynchronization Therapy 70 HDAC Inhibitor 70 phase IIb clinical 70 Augment TM 70 Milestone Payment 70 Zenvia Phase III 70 Complicated Skin 70 Fungal Infections 70 Clinical Trial Data 70 Carotid Stenting 70 Clinical Efficacy 70 Treatment Naïve 70 Clinical Trial 70 Double Blind Placebo 70 Aneurysm Repair 70 phase IIb trial 70 NAVISTAR R 70 Phase Ib II 70 Novel Antibiotic 70 Presents Preclinical Data 70 Colorectal Cancer Patients 70 Gout Drug 70 Diabetic Nephropathy 70 Commence Phase 70 Prostate Cancer Vaccine 70 Gets FDA Clearance 70 Psoriasis Drug 70 Regenerative Cells 70 Mylan Receives Approval 70 Systemic Delivery 70 TRANSDUR ™ 70 Drug Eluting 70 Bare Metal Stent 70 Disease Progression 70 Prophylactic Treatment 70 Knee Osteoarthritis 70 Subgroup Analysis 70 Ridaforolimus 70 Osteoporosis Drug 70 Drug Shows Promise 70 Anti Tumor Activity 70 Abciximab 70 Tyrosine Kinase Inhibitor 70 Adjunctive Therapy 70 Pivotal Phase II 70 Anticancer Drug 70 Safinamide 70 Placebo Controlled Trial 70 Heart Transplant Recipients 70 Ozarelix 70 sunitinib Sutent 70 Recombinant Human 70 Inhaled Insulin 70 IIa Clinical Trial 70 Blood Pressure Drug 70 Dual Antiplatelet Therapy 70 Initiate Phase II 70 Elderly Patients 70 Hepatocellular Carcinoma 70 Methylnaltrexone 70 Dasatinib 70 FDA Clears 70 PROMUS TM 70 Begins Dosing 70 Pediatric Patients 70 Biolimus A9 70 HeartMate R 70 CCX# B 69 Generic Version 69 Vicriviroc 69 Initiates Phase 69 Relapsing Multiple Sclerosis 69 Preclinical Study 69 Epilepsy Drug 69 Antiviral Activity 69 Demonstrates Efficacy 69 Receives Approvable Letter 69 Luveniq 69 TAXUS ATLAS 69 PRN FDA Approves 69 Immunotherapeutic 69 Randomized Phase II 69 Phase 2a Study 69 Xcytrin R 69 Bivalirudin 69 Chronic Heart Failure 69 Microwave Ablation System 69 REG1 Anticoagulation System 69 Cell Lymphoma 69 Thrombectomy 69 Valsartan 69 Newly Diagnosed Multiple Myeloma 69 Demonstrates Sustained 69 Initiates Phase 2b 69 TO AVOID PREGNANCY WHILE 69 LibiGel ® 69 Infarct 69 BRIM2 69 Multicenter Randomized 69 Metastatic Renal Cell Carcinoma 69 Diabetic Macular Edema 69 Recurrent Breast Cancer 69 Bosutinib 69 Shows Efficacy 69 Eculizumab 69 LEUKINE 69 Metabolic Efficiency 69 Shows Statistically Significant 69 CYPHER R Sirolimus Eluting 69 Protease Inhibitor 69 Transdermal Patch 69 FDA Okays 69 Percutaneous Coronary Intervention 69 Investigational Drug 69 Low Dose 69 WallFlex Biliary RX 69 FDA Approvable Letter 69 SinuNase TM 69 Initiated Phase 69 Balloon Angioplasty 69 Refractory Angina 69 Surgical Mesh 69 PROVENGE ® 69 Resistant Hypertension 69 Phase IIB 69 Randomized Double blind 69 TM Everolimus Eluting 69 Novel Inhibitor 69 Patients Receiving 69 Enrolls First 69 Multicenter Study 69 Dose Ranging 69 Phase IIIb study 69 fosbretabulin 69 TAXUS ® 69 vapreotide acetate 69 Pirfenidone 69 Stenting 69 Carotid 69 Sustained Efficacy 69 Bazedoxifene 69 Clolar ® 69 HER2 Positive Breast Cancer 69 Patency 69 Receives Milestone Payment 69 Testosterone Gel 69 Cetrorelix 69 Radical Prostatectomy 69 SPRYCEL ® 69 investigational humanized monoclonal antibody 69 Acute Decompensated Heart Failure 69 Percutaneous Tibial Nerve Stimulation 69 Significantly Reduced 69 Refractory Hodgkin Lymphoma 69 Phase #b/#a clinical 69 Improve Survival 69 Universal Flu Vaccine 69 Glufosfamide 69 Bare Metal Stents 69 Presents Preclinical 69 Occlusive Disease 69 Cholesterol Drug 69 Civacir 69 registrational trial 69 phase IIa 69 Golimumab 69 Adjuvant Chemotherapy 69 Is Well Tolerated 69 Orphan Status 68 JAK2 Inhibitor 68 Medoxomil 68 Sirolimus eluting Coronary Stent 68 Study Demonstrates 68 Alfimeprase 68 Appears Safe 68 Vascular Disrupting Agent 68 docetaxel Taxotere ® 68 Shows Promise Against 68 Gastric Cancer 68 Myelodysplastic Syndromes 68 Xelox 68 TRANSDUR ® 68 Interferon Alpha 68 Arthritis Drug 68 Paroxysmal Atrial Fibrillation 68 Cethromycin 68 Plaque Psoriasis 68 Peripheral Arterial 68 Catheter Ablation 68 Malignant Melanoma 68 Renal Cancer 68 dasatinib Sprycel ® 68 Parathyroid Hormone 68 Beta Blocker 68 Acute Myocardial 68 Acute Heart Failure 68 Atypical Hemolytic Uremic Syndrome 68 Therapy Evaluation 68 CYT# potent vascular disrupting 68 Spectrum Pharmaceuticals Announces 68 Breast Cancer Recurrence 68 Prospective Multicenter 68 Treatment Resistant 68 Node Positive 68 Advanced Colorectal Cancer 68 Rotavirus Vaccine 68 Vascugel 68 Enrolling Patients 68 Anticancer Compound 68 Placebo Controlled 68 Supplemental Biologics License Application 68 Chronic Hepatitis C 68 Advanced Prostate Cancer 68 Romidepsin 68 Non Invasive Treatment 68 Myeloma Patients 68 Degarelix 68 PANVAC VF 68 Tesetaxel 68 Inhalation Solution 68 HCV Protease Inhibitor 68 Recurrent Glioblastoma 68 Intracranial Aneurysms 68 Demonstrates Potential 68 Augment Injectable 68 stent DES 68 Brain Metastases 68 Stent Thrombosis 68 Seasonal Influenza Vaccine 68 ThermoDox R 68 VIVITROL ® 68 MKC# MKC# PP 68 Less Invasive 68 Phase Ib IIa 68 NEVO 68 Relapsing Remitting Multiple Sclerosis 68 Tacrolimus 68 Confirms Efficacy 68 multicenter multinational 68 Sevelamer 68 Epratuzumab 68 Infected Patients 68 Rheumatoid Arthritis Drug 68 Positive Opinion 68 Postmenopausal Women 68 Submits Response 68 Immunomedics Announces 68 Combination Therapy 68 Multiple Myeloma Patients 68 Endovascular Treatment 68 Ofatumumab 68 Combination Clinical Trial 68 GATTEX TM 68 Pharmacokinetics PK 68 cetuximab Erbitux R 68 Renal Function 68 Completes Patient Enrolment 68 EVEREST II 68 Critical Limb Ischemia 68 Diabetic Patients 68 Randomized Double Blind Placebo 68 Fabry Disease 68 Data Suggest 68 ORENCIA ® 68 ™ Paclitaxel Eluting 68 Ischemic Stroke 68 Aliskiren 68 Inhalation Aerosol 68 Effectively Treats 68 Investigational Oral 68 Androgen Deprivation Therapy 68 Myelodysplastic Syndrome MDS 68 Surgical Treatment 68 multicenter Phase III 68 Significantly Improves 68 ISTODAX ® 68 Diabetic Foot Ulcer 68 Bucindolol 68 induced macular edema 67 Coronary Artery Bypass Graft 67 Non Inferiority 67 STRIDE PD 67 Pegylated Liposomal Doxorubicin 67 PDX pralatrexate 67 Carotid Stent 67 Announces Poster Presentations 67 Teva Provides Update 67 RNAi Therapeutic 67 Treating Chronic 67 PEGINTRON TM 67 Interferon Alfa 67 Randomized Trials 67 COSTAR II 67 Thrombolysis 67 Randomized Clinical Trials 67 FDA Approves 67 Amrubicin 67 Stent Implantation 67 RNAi Therapeutics 67 Plus Ribavirin 67 Hemodialysis Patients 67 Prostate Cancer Treatment 67 Marketing Authorisation Application 67 Ambrisentan 67 TAXUS Express2 67 metastatic malignant 67 Gentium Announces 67 Medtronic CoreValve 67 Stent System 67 Hypertensive Patients 67 HuMax EGFr 67 Significantly Reduces 67 INSPIRE Trial Phase III 67 Embolic 67 ELADUR ™ 67 STARFlex R 67 Percutaneous Transluminal Coronary Angioplasty 67 Tolerability 67 Iluvien ® 67 Neoadjuvant 67 Oral Cladribine 67 Iloperidone 67 ST Elevation Myocardial 67 Randomized Controlled 67 Mycophenolate Mofetil 67 Demonstrates Potent 67 including eniluracil ADH 67 Renal Impairment 67 Stem Cell Treatment 67 occlusion CRVO 67 Levoleucovorin 67 cell lymphoma CTCL 67 Enzyme Replacement Therapy 67 Gliadel R 67 receptor tyrosine kinase inhibitor 67 Nilotinib 67 STENT 67 Tiotropium 67 EVIZON TM 67 briakinumab 67 Phase Ib clinical 67 Bepreve TM 67 Earns Milestone Payment 67 Multiple Ascending Dose 67 Chronic Myeloid Leukemia 67 Venous Thromboembolism 67 Treatment Experienced 67 Deforolimus 67 Anti Tumor 67 Follicular Lymphoma 67 Patient Treated 67 Phase 2b study 67 Anticancer Activity 67 Prostate AdenoCarcinoma Treatment 67 Soft Tissue Sarcoma 67 Ischemic 67 myelodysplastic myeloproliferative diseases 67 Receives CE Marking 67 severe hypercholesterolemia 67 Acute Coronary Syndromes 67 Drug Coated Stent 67 SABER ™ 67 Complete Remission 67 Successfully Treats 67 Carotid Artery Stenting 67 TLK# 67 MKC# MT 67 delivers fluocinolone acetonide FA 67 CUSTOM III 67 Balloon Catheter 67 Ovarian Cancer Patients 67 EchoCRT 67 Anticancer Agent 67 Prognostic Significance 67 Vascular Closure Device 67 XIENCE V Everolimus Eluting 67 aripiprazole Abilify 67 Presents Positive Preclinical 67 Vaccine Adjuvant 67 Vascular Wrap TM 67 Synta Announces 67 dual endothelin receptor antagonist 67 Non Invasive 67 Hypercholesterolemia 67 Paclitaxel Carboplatin 67 Taro Receives 67 DU #b 67 Embolization 67 Cloretazine ® 67 Kinase Inhibitor 67 Pneumococcal Vaccine 67 k Clearance 67 See CLINICAL PHARMACOLOGY 67 placebo controlled Phase 67 liver resection surgeries 67 Express2 TM 67 Sagent Pharmaceuticals Announces 67 Reduced Incidence 67 Minimally Invasive Treatment 67 Receives Fast Track 67 Chronic Hepatitis B 67 Denufosol 67 Hernia Repair 67 mGluR5 negative 67 Patent Covering 67 Fixed Dose 67 Progenitor Cells 67 phase IIb 67 Oral Mucositis 67 Desvenlafaxine Succinate 67 Patients Suffering 67 Mg Usa 67 ERBITUX cetuximab 67 dependent kinase inhibitor 67 Proven Effective 67 Irinotecan 67 Artery Disease 67 Sirolimus eluting 67 Peripheral Stent 67 Naive Patients 67 Nitinol Stent 67 Biomarker Study 67 Previously Untreated 67 Secondary Hyperparathyroidism 67 Zorbtive TM 67 Phase III multicenter 67 ALN HPN 67 WorldHeart Announces 67 Neuroprotective Effects 67 Chronic Lymphocytic Leukemia 67 Dyloject TM 67 Peginterferon Alfa 2a 67 phase IIa clinical 67 Syncria R 67 Pralatrexate 67 Replacement Therapy 67 randomized Phase IIb 67 By JENNIFER LEARN 67 Benign Prostatic Hyperplasia 67 Interferon Gamma 67 Versus Placebo 67 Dose Finding 67 occlusion PAO 67 Milestone Payment From 67 FDA APPROVES 67 Entereg R 67 PROSTASCINT R 67 Trobalt 67 Preclinical Models 67 placebo controlled Phase III 67 SUCCEED trial 67 Tanespimycin 67 Zoledronic Acid 67 acetonide FA 67 Total Knee Arthroplasty 67 Neulasta ® 67 FASLODEX 67 SPIRIT FIRST 67 Placebo Controlled Study 67 OMNARIS Nasal Spray 67 Wafer polifeprosan 67 Telbivudine 67 Interferon Beta 67 Peginterferon 67 Gene Therapy Trial 67 Diamyd Medical Diamyd 67 Phase #b/#a 66 sorafenib Nexavar 66 Raptiva R 66 Hepatitis B Vaccine 66 Radiofrequency Ablation 66 Renal Artery 66 C1 Inhibitor 66 Treat Anemia 66 Hematological Malignancies 66 Schizophrenia Treatment 66 Reports Preclinical Data 66 Catena ® 66 lexidronam injection 66 Orphan Drug Status 66 Preclinical Efficacy 66 FUSILEV ® 66 PHASE III 66 Randomised 66 MKC# 66 PEGylated anti 66 Intravenous Formulation 66 investigational antiplatelet agent 66 Valve Replacement 66 TRANSFORMS 66 Pegloticase 66 Oral Insulin 66 Cell Transplants 66 Aurora Kinase 66 PEGylated Fab fragment 66 Panzem R 66 Omacetaxine 66 Dapagliflozin 66 Pazopanib 66 ADP receptor antagonist 66 Emerging Therapies 66 Myoblast 66 XIENCE TM 66 RhuDex 66 Proves Effective 66 Myocet 66 Medullary Thyroid Cancer 66 Aortic Valve 66 Peripheral Artery Disease 66 XYOTAX TM 66 phase IIIb 66 Medtronic CoreValve ® 66 Aortic Dissection 66 Interferon beta 1a 66 Trodusquemine MSI 66 randomized controlled multicenter 66 MAGE A3 ASCI 66 Induction Therapy 66 Pemetrexed 66 Immunosuppression 66 Tumor Growth 66 Carotid Endarterectomy 66 OMNARIS HFA 66 Phase Ib study 66 Transcatheter 66 ARIXTRA R 66 Kepivance 66 endoluminal stent graft 66 multicenter Phase II 66 Bioresorbable 66 Archexin 66 Statin Therapy 66 Efficacious 66 Fracture Risk 66 Slow Progression 66 Augment ™ 66 Collaborators Present 66 complement inhibitor eculizumab 66 INCB# [003] 66 Remission Maintenance 66 Randomized Controlled Trials 66 Betaferon R 66 Kidney Transplant Recipients 66 oral dual endothelin 66 Treatment Naive Patients 66 Angiox ® 66 Osteoporosis Drugs 66 Therapeutic Vaccine 66 GTC recombinant human 66 Anti CD# Antibody 66 Febuxostat 66 biliary tract cancer 66 Fast Track Designation 66 oral prodrug 66 Embolic Protection Device 66 miconazole Lauriad R 66 Endovascular Graft 66 Myocardial Infarction Study 66 Telik logo TELINTRA 66 Liver Metastases 66 Coronary Stent System 66 Icatibant 66 MEK Inhibitor 66 Detection Device 66 Toremifene 66 Develop Novel 66 pralatrexate injection folate analogue 66 Phase 1b clinical trials 66 Ocrelizumab 66 Castration Resistant Prostate Cancer 66 AMPLATZER R 66 Hedgehog Pathway Inhibitor 66 Schizophrenia Drug 66 Daclizumab 66 Monoclonal Antibody 66 Submits Biologics License Application 66 ACE Inhibitors 66 Aloxi ® 66 Granulocyte Colony Stimulating Factor 66 EURIDIS 66 Vascular Grafts 66 rALLy clinical trial 66 Cardiovascular Events 66 Unstable Angina 66 hyaluronidase enzyme 66 Nesiritide 66 miconazole Lauriad ® 66 Aryplase 66 Intravascular 66 Symptom Relief 66 Tesamorelin 66 multicentre randomized 66 generation purine nucleoside 66 Demonstrate Significant 66 Receives SFDA Approval 66 ™ Everolimus Eluting 66 Increased Mortality 66 Treatment Regimen 66 Resection 66 Nicotine Vaccine 66 Receives Marketing Authorization 66 StaphVAX R 66 Minimally Invasive Procedure 66 Acute Attacks 66 R Saizen R 66 Cardiac Resynchronization 66 candesartan cilexetil 66 UPLYSO 66 Blood Thinner 66 Inhaled Corticosteroids 66 EOquin TM 66 PFO migraine 66 Receptor Antagonist 66 Antimicrobial Coating 66 Receptor Agonist 66 Adalimumab 66 DuraHeart TM 66 VIVUS Announces 66 Resubmission 66 refractory chronic lymphocytic 66 pan HDAC inhibitor 66 Radiofrequency Ablation RFA 66 STELARA TM 66 Treatment Naïve Patients 66 Cardiovascular Outcomes 66 Inflammatory Markers 66 Smooth Muscle 66 Advanced Pancreatic Cancer 66 eluting stent 66 Hormone Receptor Positive 66 Enoxaparin 66 Announces Tentative Approval 66 ENESTnd 66 Antiepileptic Drug 66 HCV SPRINT 66 Lamotrigine 66 Early Relapsing Multiple 66 Vitrasert R 66 stage IIIB 66 HER2 Positive 66 Edge STudy 66 Significantly Improved 66 ENDEAVOR II 66 Dalbavancin 66 Second Pivotal Phase 66 Implantable Device 66 Disease Modifying 66 Blinatumomab 66 Central Retinal Vein 66 Patient Accrual 66 Endoprosthesis 66 Lung Cancer Survival 66 Lung Cancer Patients 66 Melphalan 66 Left Atrial Appendage 66 Potent Antiviral Activity 66 LUMINATE 66 Begins Clinical Trial 66 Kamada AAT 66 Marketing Authorization Application 66 Liver Failure 66 HoFH 66 PROMUS ® 66 Phase IIa Trial 66 BRIM3 66 Chemoradiation 66 Receives CE 66 Lung Cancers 66 Oral Formulation 66 Submits Investigational 66 ARIXTRA 66 Predict Risk 66 BENLYSTA ® 66 multicenter prospective 66 CORTOSS R 65 Systemic Sclerosis 65 Phase III Psoriasis 65 Cardiogenic Shock 65 Antigen Specific 65 Antibody Drug Conjugate 65 lucinactant 65 Aortic Stenosis 65 Cites Positive 65 Pharmaceuticals Initiates 65 SUTENT ® 65 HepaSphere 65 CINTREDEKIN BESUDOTOX 65 Multicenter Phase 65 acute PAO 65 Sipuleucel T 65 Mipomersen 65 Combo Therapy 65 Breast Cancer Treatment 65 Rotary VAD 65 Chronic Sinusitis 65 CHAMPION PCI 65 Matrix Phase 2b 65 SUPPRELIN R LA 65 Artificial Pancreas 65 selective A2A adenosine receptor 65 docetaxel Taxotere R 65 Diabetic Neuropathic Pain 65 PRECISE 65 Transdermal System 65 PREOS R 65 NYHA Class II 65 pain palliation 65 aneurysms AAA 65 Extended Dosing 65 R bendamustine hydrochloride 65 ORLive Presents 65 Chemotherapy Regimen 65 investigational pharmacologically unique 65 budesonide foam 65 Neulasta R 65 Certolizumab 65 topically applied SEPA 65 acyclovir Lauriad R 65 urethral bulking agent 65 Premature Infants 65 Diabetic Neuropathy 65 Myelofibrosis 65 NICE Recommends 65 J Am Coll 65 multicenter randomized placebo controlled 65 oral ridaforolimus 65 Plicera 65 Tocilizumab 65 Mouse Model 65 Accelerated Partial Breast Irradiation 65 FDA Orphan Drug 65 ALVESCO ® 65 multicenter Phase 65 Tigecycline 65 Azacitidine 65 evaluating tivozanib 65 Contrast Agent 65 Epidermal Growth Factor Receptor 65 Endeavor drug eluting 65 Bone Augmentation Material 65 Fidaxomicin 65 randomized controlled Phase 65 Tipranavir 65 Pertuzumab 65 huC# DM4 65 Cotavance 65 diarrhea fatigue asthenia 65 Diabetic Foot Ulcers 65 Unresectable 65 Novel Mechanism 65 DIRECT Trial 65 Peginterferon alfa 2b 65 evaluating mipomersen 65 ARCOXIA 65 Known hypersensitivity 65 Intervention Effectiveness 65 samarium Sm 65 Benign Prostatic Hyperplasia BPH 65 Telaprevir VX 65 albiglutide 65 Successfully Treated 65 comparing XIENCE V 65 Endometrial Cancer 65 Hepatitis C Patients 65 Erectile Dysfunction Drug 65 Relapsed Refractory 65 paclitaxel eluting 65 Potent Inhibitor 65 GEM OS2 65 IMPACT IMmunotherapy 65 Angiographic 65 assessing T DM1 65 Lowers Risk 65 Uterine Fibroid Embolization 65 Tolvaptan 65 Skeletal Muscle 65 Corneal Transplant 65 initiated Phase Ib 65 Decompensated Heart Failure 65 FDA Approval 65 Nebulized 65 Slows Progression 65 Dupuytren Disease 65 Phase #/#a 65 Seasonal Allergic Rhinitis 65 Posaconazole 65 BioElectronics Announces 65 Anturol TM 65 COMFORT II 65 Endovascular Valve Edge 65 Loceryl ® 65 Val HeFT 65 colesevelam HCl 65 Therapeutic Antibody 65 Metabolic Disorder 65 ELADUR TM 65 Raptiva ® 65 liposomal formulation 65 zotarolimus eluting stent 65 INTEGRILIN R 65 Vertebral Fracture 65 Xanafide

Back to home page